Literature DB >> 15929099

Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition.

Serhan Alkan1, Qin Huang, Melek Ergin, Mitchell F Denning, Sucha Nand, Tazeen Maududi, Gladell P Paner, Fulya Ozpuyan, Keith F Izban.   

Abstract

Recent studies have suggested that protein kinase C (PKC) activation plays an important role in survival of chronic lymphocytic leukemia (CLL). In order to characterize the role of PKC in CLL, we investigated the expression pattern of PKC isoforms in CLL cells (7 cases) and evaluated the effect of PKC inhibition on the survival of CLL cells (20 cases). Expression of the classical PKC isoforms beta and gamma, the novel isoform delta and the atypical isoform zeta was seen in all analyzed patient samples by Western blot analysis. Expression of the PKC isoforms alpha, epsilon, and iota was variable. Following incubation with the PKC inhibitor, safingol, CLL cells underwent marked apoptosis in all cases. In order to characterize the molecular events associated with the apoptotic effect of PKC inhibition, gene expression patterns in CLL cells were evaluated by cDNA-microarray analysis. Following safingol treatment, several genes showed marked downregulation and PKC-related proteins demonstrated decreased hybridization signals. Among these proteins, CREB and Daxx were further studied by using Western blotting, nuclear binding assay and confocal immunofluorescent microscopy. These studies showed significant inhibition of these proteins, consistent with the results of microarray gene analysis. Overall, these findings suggest that PKC activation is important for CLL cell survival and that inhibitors of PKC may have a role in the treatment of patients with CLL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15929099     DOI: 10.1002/ajh.20352

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

Review 2.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

Review 3.  Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Authors:  Julhash U Kazi; Nuzhat N Kabir; Lars Rönnstrand
Journal:  Med Oncol       Date:  2013-10-31       Impact factor: 3.064

4.  Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.

Authors:  Mary K McKenna; Sunil K Noothi; Sara S Alhakeem; Karine Z Oben; Joseph T Greene; Rajeswaran Mani; Kathryn L Perry; James P Collard; Jacqueline R Rivas; Gerhard C Hildebrandt; Roger A Fleischman; Eric B Durbin; John C Byrd; Chi Wang; Natarajan Muthusamy; Vivek M Rangnekar; Subbarao Bondada
Journal:  Blood       Date:  2018-04-25       Impact factor: 22.113

5.  Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes.

Authors:  Rinako Nakagawa; Milica Vukovic; Anuradha Tarafdar; Emilio Cosimo; Karen Dunn; Alison M McCaig; Ailsa Holroyd; Fabienne McClanahan; Alan G Ramsay; John G Gribben; Alison M Michie
Journal:  Haematologica       Date:  2015-01-23       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.